ImmunityBio (IBRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of ImmunityBio (IBRX)
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.
Key Insights
Critical company metrics and information
Share Price
$4.96Market Cap
$3.46 BillionTotal Outstanding Shares
696.83 Million SharesTotal Employees
672Dividend
No dividendIPO Date
March 10, 2021SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.immunitybio.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Investing Activities | $65.03 Million |
Net Cash Flow From Investing Activities, Continuing | $65.03 Million |
Net Cash Flow From Financing Activities, Continuing | $15.58 Million |
Net Cash Flow From Operating Activities | $-98.76 Million |
Net Cash Flow | $-18.15 Million |
Net Cash Flow From Operating Activities, Continuing | $-98.76 Million |
Net Cash Flow, Continuing | $-18.15 Million |
Net Cash Flow From Financing Activities | $15.58 Million |
Income Statement
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Net Income/Loss Available To Common Stockholders, Basic | $-85.73 Million |
Operating Income/Loss | $-80.25 Million |
Basic Earnings Per Share | $0.12 |
Basic Average Shares | $695.89 Million |
Diluted Earnings Per Share | $0.14 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Cost Of Revenue | $0.00 |
Revenues | $6.11 Million |
Costs And Expenses | $91.86 Million |
Operating Expenses | $86.36 Million |
Interest Expense, Operating | $29.32 Million |
Income/Loss From Continuing Operations After Tax | $-85.75 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Selling, General, and Administrative Expenses | $35.92 Million |
Nonoperating Income/Loss | $-5.50 Million |
Research and Development | $50.44 Million |
Net Income/Loss | $-85.75 Million |
Diluted Average Shares | $697.96 Million |
Net Income/Loss Attributable To Parent | $-85.73 Million |
Income Tax Expense/Benefit | $0.00 |
Income/Loss From Equity Method Investments | $0.00 |
Benefits Costs and Expenses | $91.86 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $23000.00 |
Income/Loss From Continuing Operations Before Tax | $-85.75 Million |
Balance Sheet
July 1, 2024 to September 30, 2024
Metric | Value |
---|---|
Equity Attributable To Parent | $-745.15 Million |
Noncurrent Assets | $201.42 Million |
Current Liabilities | $60.96 Million |
Fixed Assets | $139.28 Million |
Inventory | $1.96 Million |
Liabilities And Equity | $364.57 Million |
Other Current Assets | $161.19 Million |
Assets | $364.57 Million |
Current Assets | $163.15 Million |
Other Non-current Assets | $62.13 Million |
Noncurrent Liabilities | $1.05 Billion |
Equity Attributable To Noncontrolling Interest | $986000.00 |
Equity | $-744.16 Million |
Liabilities | $1.11 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.